Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$340.86K$340.86Kno prior Q1 2019 on file Net Income-$4.66M-$4.66MN/M vs Q1 2019 EPS Diluted-$0.05-$0.05N/M vs Q1 2019 Operating Income-$2,648,647N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
Margins · derivedOperating margin-777.1%
Net margin-1366.5%
ended Mar 31, 2020 · filed Jun 29, 2020 · 90 d after period end